You are here

anti-PD-L1

Boehringer, BeiGene enter manufacturing pact for PD-1 drug

Boehringer, BeiGene enter manufacturing pact for PD-1 drug

Biopharma Dive

Boehringer Ingelheim

drug manufacturing

Flag link:

Regeneron, Sanofi are ready to debut the 6th PD-1/L1. Is it still possible to stand out from the growing crowd?

Regeneron, Sanofi are ready to debut the 6th PD-1/L1. Is it still possible to stand out from the growing crowd?

Endpoints

advanced cutaneous squamous cell carcinoma

Flag link:

Pfizer, Merck KGaA run into a severe setback as PD-L1 drug Bavencio fails in PhIII gastric cancer study

Pfizer, Merck KGaA run into a severe setback as PD-L1 drug Bavencio fails in PhIII gastric cancer study

Endpoints

Flag link:

An explosion of PD-1/L1 checkpoint studies is crowding the industry pipeline — and that’s a problem

An explosion of PD-1/L1 checkpoint studies is crowding the industry pipeline — and that’s a problem

Endpoints

drug development

Flag link:

Sanofi, Regeneron earn ‘breakthrough’ status for a fast-track drug out to prove PD-1 dominance

Sanofi, Regeneron earn ‘breakthrough’ status for a fast-track drug out to prove PD-1 dominance

Endpoints

breakthrough status

Flag link:

Celgene joins the PD-1 checkpoint club, bagging BeiGene drug with $413M down and $1B on the table

Celgene joins the PD-1 checkpoint club, bagging BeiGene drug with $413M down and $1B on the table

Endpoints

Flag link:

Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?

Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?

Endpoints

Bristol-Myers Squibb

Flag link:

AstraZeneca delays PD-L1 data in rejig of phase 3 program

AstraZeneca delays PD-L1 data in rejig of phase 3 program

Fierce Biotech

clinical trials

Flag link:

Your attention, please: AstraZeneca asks for a moment of rapt silence, for a BLA acceptance?

Your attention, please: AstraZeneca asks for a moment of rapt silence, for a BLA acceptance?

Endpoints

Flag link:

FDA Grants Merck Priority Review for Keytruda Drug (MRK)

FDA Grants Merck Priority Review for Keytruda Drug (MRK)

Investopedia

priority review

non-small cell lung cancer

Flag link:

Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class

Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class

Market Realist

Bristol-Myers Squibb

Flag link:

New anti-PD1 drugs overpriced, ICER says

New anti-PD1 drugs overpriced, ICER says

BioPharma Dive

Bristol-Myers Squibb

Flag link:

Amgen's Biosimilar Approval And Astra's Anti-PD-L1 Data

Amgen's Biosimilar Approval And Astra's Anti-PD-L1 Data

Seeking Alpha

Flag link:

AstraZeneca wins FDA breakthrough status for key cancer drug

AstraZeneca wins FDA breakthrough status for key cancer drug

Yahoo/Reuters

breakthrough status

Flag link:

Pfizer, Merck KGaA launch two more PhIII trials for avelumab

Pfizer, Merck KGaA launch two more PhIII trials for avelumab

Fierce Biotech

Flag link:

Genentech's PD-L1 breakthrough star 'atezo' positioned to vault ahead on cancer

Genentech's PD-L1 breakthrough star 'atezo' positioned to vault ahead on cancer

Fierce Biotech

Flag link:

AstraZeneca and Lilly to test new cancer drug combination

AstraZeneca and Lilly to test new cancer drug combination

Yahoo/Reuters

Flag link:

FDA Grants Breakthrough Therapy Designation To Genetech’s Cancer Immunotherapy

FDA Grants Breakthrough Therapy Designation To Genetech’s Cancer Immunotherapy

Bidness Etc.

breakthrough therapies

non-small cell lung cancer

Flag link:

Merck KGaA seeks partner for immuno-oncology drug by year-end

Merck KGaA seeks partner for immuno-oncology drug by year-end

Yahoo/Reuters

immuno-oncology

Flag link:

Pharma’s Huge Bet on Immunotherapies

Pharma’s Huge Bet on Immunotherapies

Motley Fool

anti-PD-1 immunotherapy

Bristol-Myers Squibb

Flag link:

Pages